Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

Young Seok Ju(Wellcome Sanger Institute), Ludmil B. Alexandrov(Wellcome Sanger Institute), Moritz Gerstung(Wellcome Sanger Institute), Sancha Martin(Wellcome Sanger Institute), Serena Nik-Zainal(Wellcome Sanger Institute), Manasa Ramakrishna(Wellcome Sanger Institute), Helen Davies(Wellcome Sanger Institute), Elli Papaemmanuil(Wellcome Sanger Institute), Gunes Gundem(Wellcome Sanger Institute), Adam Shlien(Wellcome Sanger Institute), Niccolò Bolli(Wellcome Sanger Institute), Sam Behjati(Wellcome Sanger Institute), Patrick Tarpey(Wellcome Sanger Institute), Jyoti Nangalia(University of Cambridge), Charles Massie(University of Cambridge), Adam P. Butler(Wellcome Sanger Institute), Jon W. Teague(Wellcome Sanger Institute), George S. Vassiliou(University of Cambridge), Anthony R. Green(University of Cambridge), Ming‐Qing Du(Cambridge University Hospitals NHS Foundation Trust), Ashwin Unnikrishnan(Cancer Institute of New South Wales), John E. Pimanda(Cancer Institute of New South Wales), Bin Tean Teh(Duke-NUS Medical School), Nikhil C. Munshi(Boston University), Mel Greaves(Institute of Cancer Research), Paresh Vyas(University of Oxford), Adel K. El‐Naggar(The University of Texas MD Anderson Cancer Center), Tom Santarius(Cambridge University Hospitals NHS Foundation Trust), V. Peter Collins(Cambridge University Hospitals NHS Foundation Trust), Richard G. Grundy(University of Nottingham), Jack A. Taylor(Triangle), D Neil Hayes(University of North Carolina at Chapel Hill), David Malkin(University of Toronto), ICGC Breast Cancer Group(Institute of Cancer Research), ICGC Chronic Myeloid Disorders Group(Cambridge University Hospitals NHS Foundation Trust), ICGC Prostate Cancer Group(University of Cambridge), Christopher S. Foster(University of East Anglia), Anne Y. Warren(Institute of Cancer Research), Hayley C. Whitaker(University of East Anglia), Daniel S. Brewer(University of East Anglia), Rosalind A. Eeles(Institute of Cancer Research), Colin Cooper(University of East Anglia), David E. Neal(University of Cambridge), Tapio Visakorpi(Royal National Orthopaedic Hospital), William B. Isaacs(The University of Texas MD Anderson Cancer Center), G. Steven Bova(University of Cambridge), Adrienne M. Flanagan(Royal National Orthopaedic Hospital), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Andy G. Lynch(University of Cambridge), Patrick F. Chinnery(University of Cambridge), Ultan McDermott(Cambridge University Hospitals NHS Foundation Trust), Michael R. Stratton(Wellcome Sanger Institute), Peter J. Campbell(University of Cambridge)
eLife
September 30, 2014
Cited by 499Open Access
Full Text

Abstract

Recent sequencing studies have extensively explored the somatic alterations present in the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, the origins and impact of cancer-associated mutations in mtDNA are unclear. In this study, we analyzed somatic alterations in mtDNA from 1675 tumors. We identified 1907 somatic substitutions, which exhibited dramatic replicative strand bias, predominantly C > T and A > G on the mitochondrial heavy strand. This strand-asymmetric signature differs from those found in nuclear cancer genomes but matches the inferred germline process shaping primate mtDNA sequence content. A number of mtDNA mutations showed considerable heterogeneity across tumor types. Missense mutations were selectively neutral and often gradually drifted towards homoplasmy over time. In contrast, mutations resulting in protein truncation undergo negative selection and were almost exclusively heteroplasmic. Our findings indicate that the endogenous mutational mechanism has far greater impact than any other external mutagens in mitochondria and is fundamentally linked to mtDNA replication.


Related Papers

No related papers found

Powered by citation graph analysis